The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
AstraZeneca’s research and development site in Gothenburg, Sweden. Credit: AstraZeneca.
Subscribe to our email newsletter
The therapeutic schedule for Imfinzi with Astellas Pharma and Pfizer’s drug involves neoadjuvant treatment prior to radical cystectomy, followed by single-agent Imfinzi as adjuvant therapy.
The FDA granted the clearance under priority review based on findings from the multi-centre VOLGA Phase III clinical study (NCT04960709), published in The New England Journal of Medicine and presented at the 2026 European Society for Medical Oncology Congress.
In the trial, the perioperative regimen reduced the risk of disease progression, recurrence, omitted surgery, or death by 49% compared with radical cystectomy with or without approved adjuvant treatment.
Two-year event-free survival reached an estimated 64% with the regimen, compared with 45% in the control arm, where median event-free survival was 12.1 months.
Overall survival results demonstrated a 42% decrease in the risk of death, with two-year survival rates estimated at 78% versus 69%.
Grade 3 and 4 adverse events arising from any cause occurred in 64% of individuals treated with the combination, compared with 44% in the comparator arm, with no new safety signals reported.
Patient-reported quality of life was maintained following surgical intervention.
AstraZeneca oncology haematology business unit executive vice president Dave Fredrickson said: “Today’s approval offers a novel Imfinzi-based regimen that almost halved the risk of disease recurrence and reduced the risk of death by 42% in the VOLGA trial, allowing physicians to optimise treatment for patients in this curative-intent setting.
“As our third bladder cancer indication in two years, this approval reinforces Imfinzi as an immunotherapy backbone across muscle-invasive and non-muscle-invasive disease.”
Muscle-invasive tumours account for roughly one-quarter of all bladder cancer cases, with approximately 16,000 individuals in the US expected to receive treatment in 2026.
Impaired renal function or other comorbidities prevent up to 50% of patients from tolerating cisplatin-based chemotherapy, leaving radical cystectomy alone as the historical standard despite frequent recurrences.
Outside the US, regulatory applications based on the 695-patient trial remain under review in the European Union, Japan, and other territories.
In May this year, AstraZeneca received approval from the US FDA for Imfinzi in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for adult patients with BCG-naïve, high-risk non-MIBC. Imfinzi holds multiple approvals in the US across lung, bladder, gastrointestinal, and gynecological cancers.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.